Vaxent

nnFor more than fifty years, the company have been plotting the route in Allergy medicine. The company have been leading generations of allergists to some of the most discoveries in this science:na vaccine by bronchial route, a vaccine by nasal route, the Methacholine Challenge Test, the Test Dose for foodstuff or additives allergy, and allergens adsorbed on single-use needles.

ImmBio is a vaccine company developing vaccine systems. The portfolio addresses areas of high unmet need, where the risk and consequence of infection are severe.

FluGen is developing a universal influenza vaccine. The REDEE FLU influenza vaccine contains mutations in the M2 gene of the virus. The mutated virus can infect cells, express the entire spectrum of influenza RNA and proteins, yet fails to produce any infectious virus particles.

Creatogen, a spin-off from the Max Planck Institute for Infection Biology in Berlin, develops bacterial carriers for oral delivery to treat and prevent acute and chronic diseases caused by an imbalance of the immune system.

The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology. The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University. Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See www.savine.com

Developing genetically modified vaccines to protect against common seasonal influenza and emergent pandemic influenza. Formed to commercialize patented vaccine and virus technologies developed at the Mount Sinai School of Medicine, Vivaldi's program represents a approach to flu vaccine development and production and a major advance over flu vaccines available today.